Announcement on the progress of litigation execution by a subsidiary of Kangmei Pharmaceutical.
Announcement of Kangmei Pharmaceuticals' expected half-year performance in 2024.
Announcement of Kangmei Pharmaceutical's Revocation of Other Risk Warnings and Suspension of Stock Trading
Review Opinion on the Self-Inspection Report of Kangmei Pharmaceutical Co., Ltd. by Tianzhi International Certified Public Accountants (Special General Partnership).
Report on Self-Inspection of Kangmei Pharmaceutical
Legal Opinion of Guangdong Xinda Law Firm on Kangmei Pharmaceutical Co., Ltd.'s Application for the Cancellation of Other Risk Warnings
Announcement from Kangmei Pharmaceutical regarding the company's application to cancel other risk warnings for stocks.
Announcement of the resolution of the 3rd interim meeting of the 9th board of directors of Kangmei Pharmaceutical Co., Ltd. for the year 2024.
Tianzhi International Accounting Firm (Special General Partnership) Special Instructions on Matters Related to the 2023 Annual Report Supervision Work Letter of Kangmei Pharmaceutical Co., Ltd.
Kangmei Pharmaceutical's Reply Notice on the Shanghai Stock Exchange's “Information Disclosure and Supervision Work Letter on the 2023 Annual Report of Kangmei Pharmaceutical Co., Ltd.”
Kangmei Pharmaceutical's announcement on receipt of court enforcement ruling
Kangmei Pharmaceutical's announcement on holding a performance briefing for the first quarter of 2023 and 2024
Announcement of Resolutions of Kangmei Pharmaceutical's 2023 Annual General Meeting of Shareholders
Legal Opinion of Guangdong Cinda Law Firm on the 2023 Annual General Meeting of Shareholders of Kangmei Pharmaceutical Co., Ltd.
Kangmei Pharmaceutical's 2024 First Quarter Report
Announcement of Resolutions of the Second Interim Meeting of the 9th Board of Directors of Kangmei Pharmaceutical in 2024
Announcement of Resolutions of the Second Interim Meeting of the 9th Board of Supervisors of Kangmei Pharmaceutical in 2024
Kangmei Pharmaceutical's 2023 Annual General Meeting of Shareholders Meeting Materials
Tianji International Accounting Firm (Special General Partnership) on Kangmei Pharmaceutical Audit Report (2023)
Kangmei Pharmaceutical's 2023 Independent Director Debriefing Report (Luo Tao)
No Data